Trial Profile
ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary) ; Carboplatin; Paclitaxel
- Indications Endometrial cancer
- Focus Therapeutic Use
- Acronyms ENGOT-EN1/FANDANGO
- 09 Mar 2022 This trial has been Discontinued in Denmark(End date:2022-03-01), according to European Clinical Trials Database record.
- 07 Jan 2022 Status changed from active, no longer recruiting to completed.
- 30 Oct 2019 Status changed from recruiting to active, no longer recruiting.